The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive disorder characterized by thrombocytopenia, small platelets, eczema, recurrent infections, and immunodeficiency. Besides the classic WAS phenotype, there is a group of patients with congenital X-linked thrombocytopenia (XLT) who have small platelets but only transient eczema, if any, and minimal immune deficiency. Because the gene responsible for WAS has been sequenced, it was possible to correlate the WAS phenotypes with WAS gene mutations. Using a fingerprinting screening technique, we determined the approximate location of the mutation in 13 unrelated WAS patients with mild to severe clinical symptoms. Direct sequence analysis of cDNA and genomic DNA obtained from HE WISKOTT-ALDFUCH syndrome (WAS) is an Xlinked recessive disorder characterized by thrombocytopenia, small platelet volume, eczema, recurrent bacterial and viral infections, autoimmune diseases, increased risk of maligancies, and abnormal B-and T-cell f~ncti0n.l.~ Patients with WAS respond poorly to immunization with polysaccharides and certain protein antigen^,^.^ and lymphocyte proliferation in response to mitogens and antigens is variably depre~sed.~ Distinguishable from this classic WAS phenotype are boys with X-linked thrombocytopenia (XLT) whose platelets are small and who either are free of eczema6"' or have a history of only mild and transient Most patients with XLT have normal susceptibility to infections and normal immune functions. The gene for XLT has been mapped to Xpll.22, the same band to which the classic WAS phenotype had been mapped?~"~12
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The gene responsible for WAS has been isolated, cloned, and ~equenced.'~ Encoded by 12 exons and composed of 1,823 bp, the cDNA encodes a 502-amino acid, proline-rich protein (WAS protein) of unknown function that appears to be of central importance for the function of hematopoietic cell lineages.13.14 WAS gene transcript was absent in 2 of 5 Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell lines (B-LCL) derived from affected male patients, and sequence analysis of genomic DNA showed three independent mutations, strongly suggesting that the newly identified gene was the WAS gene."
To determine the mutation pattern of the WAS gene and to correlate location and type of mutations with clinical phenotypes, we studied 13 additional unrelated WAS families whose affected members presented with mild to severe disease. Twelve unique mutations, which were distributed throughout the WAS gene, were identified and included insertions, deletions, and point mutations resulting in stop codons, amino acid substitutions, exon skipping, or splicing defects.
T

MATERIALS AND METHODS
Patients and Their Phenotypes
Affected members of 13 unrelated WAS families with variable phenotypes were included in this analysis ( Table 1 severity of WAS-associated symptoms was scored from 1 to 5 , based on the following criteria. A score of 1 was given to patients with thrombocytopenia and small sized platelets, but without any other symptoms or clinical findings. Patients with platelet abnormalities and a history of mild, transient, eczema, with or without minor infections, received a score of 2. Patients with persistent but manageable eczema, with recurrent infections, or with both received a score of 3. Those patients with persistent and difficult to control eczema associated with frequent potentially life-threatening infections were scored as 4. A score of 5 was assigned if patients presenting with eczema and/or frequent infections developed autoimmune disease. Seven of the 13 families reported more than 1 affected male patient.
Of the 13 unrelated WAS patients included in this study, 1 infant (BM), diagnosed prenatally by linkage analysis and receiving a transplant at 1 month of age with bone marrow from an HLA-matched sibling had not been observed long enough to be scored; up to the time of marrow transplantation, BM's only findings were thrombocytopenia, small platelets, and petechiae. However, his older brother, who died of meningitis at 6 years of age, had severe clinical symptoms and was assigned a score of 4. Patient AR, who presented with congenital thrombocytopenia and persistent small platelet size, but 3798 ZHU ET AL without eczema or increased susceptibility to infections, was evaluated carefully and found to be immunologically normal; he was given a score of 1. However, shortly after splenectomy, AR developed pneumococcal sepsis, suggesting that he may have mild immune deficiency. All of the remaining 11 patients had additional symptoms, including various degrees of immune abnormalities. Three patients (CS, JS, and BG) with transient, mild eczema and infrequent infections responding well to antibiotics were given scores of 2. One patient (EA) whose persistent eczema and infections were wellcontrolled by standard therapy was given a score of 3. The remaining 7 patients had severe clinical symptoms and were given a score of 4 if without and a score of 5 if with symptoms of an autoimmune disorder.
Cell Lines
B-LCLs established by inoculating peripheral blood mononuclear cells (PBMCs) with supernatants from the marmoset cell line B95.8I5 were available from all but 1 WAS patient. From patient AR, mRNA and genomic DNA were isolated from frozen spleen cells that had been obtained during splenectomy.
Selection of Primers
Primers for amplification of cDNA and genomic DNA and for dideoxynucleotide fingerprinting were selected from the known cDNA and genomic DNA sequences of the WAS gene'3 and designed to identify the mutations of our patient population (Table 2) .
RNA Isolation and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RNA isolation and RT-PCR were performed as previously described. 16 Briefly, total RNA was isolated from B-LCLs or spleen cells using a single-step method and Trizol (GIBCO BRL, Gaithersburg, MD). The first-strand cDNA was synthesized by incubating 2.5 pg of total RNA with oligo (dT) as primer using the Superscrip Preamplification System kit (GIBCO BRL), as recommended by the manufacturer. The WAS protein cDNA was amplifed by PCR in two overlapping fragments. For reaction 1 (Table 2) U of the Taq Extender PCR additive (Stratagene, La Jolla, CA), and 2.5 U Taq polymerase in a total volume of 100 p L at 94°C for 1 minute, 57°C for 1 minute, 72°C for 1.5 minutes, and a final extension step at 7 2 T for 5 minutes for 35 cycles. The PCR products were purified by agarose gel electrophoresis.
Dideoxynuckotide Fingerprinting (ddF) and Direct Sequencing of cDNA
To screen the amplified WAS protein cDNA for mutations, we used the modified ddF method originally described by Sarkar et a1" and the fmol cycle sequencing kit (Promega, Madison, WI). Briefly, 50 to 75 ng of amplified cDNA, 2 pL ddC/dC mixture, 0.25 pL (0.25 pmol) "P end-labeled primer, 1.25 pL 5X sequence buffer, 0.25 pL Taq polymerase, and distilled H20 to a total volume of 6 pL was incubated in an automatic DNA thermal cycler (PerkinElmer, Norwalk, CT) at 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 minute for 30 cycles. The resulting products were electrophoresed in 5% polyacrylamide nondenaturing gels at 4°C. The mutations suggested by ddF were confirmed by direct sequenc- Primers listed for reactions 1 and 2 were used to amplify WAS protein cDNA in two overlapping fragments. The other primers (reactions 3 ing using selected primers and the fmol cycle sequencing kit (Promega) according to the manufacturer's recommendation.
DNA Pur$cation and Sequencing of Genomic DNA
DNA was extracted from B-LCLs or spleen cells as previously described.I6 Purified genomic DNA samples were amplified with primer pairs (Table 2) designed to span the suspected mutation sites.
The PCR conditions used were as follows. For reactions 3 through 7 (Table 2) , the samples were incubated for 5 minutes at 94°C followed by 30 cycles at 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute. The conditions for reactions 8 and 9 (Table 2) were identical to those for reaction 2, which have been already described. The amplified DNA fragments were separated by agarose gel electrophoresis and electroelution. Direct sequencing was perfomed by the dideoxynucleotide chain termination method," using either the sequenase DNA sequencing kit (US Biochemical Corp, Cleveland, OH) or the fmol cycle sequencing kit (Promega) as recommended by the manufacturers.
Northern Blot Analysis
Poly A (+) mRNA samples isolated from 30 p g total RNA with the PolyATtract mRNA isolation system (Promega) were electropho- 
RESULTS
Screening for Mutations by ddF
To identify the approximate location of mutations, we screened the entire coding region and part of the noncoding region of WAS protein cDNA with ddF. This procedure showed abnormal sequences in all 13 patients reported here and allowed us to predict the approximate location of each defect. Additional WAS patients need to be studied in a similar manner to determine the overall effectiveness of this method in detecting mutations.
Direct Sequencing of cDNA and Genomic DNA
Only after introducing the Taq Extender
PCR additive provided by Stratagene were we able to consistently obtain PCR products from exons 10 and 11. Single nucleotide substitutions (point mutations), observed in the genomic DNA of 10 patients with nine novel mutations, were the most frequent mutations; in the remaining 3 patients, we found insertions or deletions of nucleotides within the genomic DNA ( Table I and Fig 1) .
Point mutations resulting in XLT. Two unrelated patients (AR and CS) with a mild phenotype (scores of l and 2) had the same missense mutation, a C * T transition at position 290 in exon 2, resulting in the substitution of arginine with cystein (Arg86Cys). This mutation had no effect on the amount of mRNA (Fig 2, lane 2) . Patient JS had a C + A transversion at position 174 in exon 2, resulting in the substitution of alanine with aspartic acid (Ala47Asp) and a marked reduction in the amount of transcript (data not shown). cDNA analysis of patient BG showed a deletion of the last 13 bp of exon 9 (bp953-965) due to an A + G transition at position 953 of genomic DNA. Instead of changing the normal codon 307 from ATG (Met) to GTG (Val), this mutation activates a cryptic splice site at 13 nucleotides 5' to the normal splice site (5'-GAGgtgagg-3' ; Fig 3) . The deletion of 13 nucleotides results in frameshift and premature termination 137 triplets downstream in exon IO. Northern blot analysis of BG's B-LCLs indicates markedly reduced transcript (Fig 2, lane 8) .
Point mutations resulting in classic WAS. Patient MS with a severe form of WAS had a G + A transition at position 407 in exon 4, resulting in the substitution of glycine with arginine (Glyl25Arg). This missense mutation did not interfere with transcription (Fig 2, lane 3) . Two patients (DM and TH), both with severe WAS, were found to have nonsense mutations due to single nucleotide substitutions resulting in termination codons. DM had a C * T transition at position 71 in exon 1 (Arg13Ter) and normal amount of transcript (Fig 2, lane 4) . TH had a C + T transition at position 995 in exon 10 (Arg321Ter) and reduced transcript (Fig 2, lane  5) . The PCR-amplified cDNA obtained from a B-LCL of patient RM consisted of a strong band that migrated faster than the normal product and a second, much fainter band (<25%) of normal size. Direct sequence analysis of the faster migrating, dominant band of RM's amplified cDNA showed a deletion of 87 bp, representing exon 3. Sequence analysis of genomic DNA showed that the skipping of exon 3 was the direct consequence of a nonsense mutation, a C 4 T transition, affecting nucleotide 329 in exon 3 ( Fig 4) ; this would result in the formation of a termination codon (Gln99Ter). To explore the possibility of alternative splicing, we sequenced individual clones of RM's cDNA after PCR amplification. Ten clones were found to have exon 3 deleted and 3 clones were of normal size and contained the termination codon. Northern blot analysis failed to detect transcript (Fig 2, lane 6) , suggesting that both mRNA populations are poorly transcribed or unstable, although definitively present as shown by RT-PCR. The t -P c transition at position +2 of the 5' splice site of intron 9 of patient MB resulted in the activation of a cryptic splice site and the insertion of the 5' segment of intron 9 consisting of 114 bp into this patient's cDNA. This insertion caused frameshift and a termination codon within the inserted segment. On Northern blot, the amount of mRNA detected was severely reduced and appeared to migrate slower (Fig 2, lane 7) . In patient BM, the (Fig 2, lane 9) . A protein made from this transcript would lack 38 amino acids encoded by exon 11 and, because of frameshift, would be unstable. Insertions and deletions affecting genomic DNA resulting in classic WAS. In 3 unrelated WAS patients, the mutations were due to the insertion or the deletion of nucleotides from genomic DNA. EA was found to have a single nucleotide (C) insertion between nucleotides 61 and 65 (GCCCG GCCCCG) of exon I, affecting codon 11 and resulting in frameshift and premature termination at codon 37; the amount of mRNA on Northern blot was markedly reduced (Fig 2, lane 10) . A deletion and insertion of small DNA fragments, observed in genomic DNA of patient PP, resulted in a new splice site and the addition of 13 bp derived from intron 10 (Fig 5) , causing premature termination close to the 3'end of exon 12. A B-LCL derived from this patient contained abundant mRNA (Fig 2, lane 11) . A protein made from this transcript would be 4 amino acids shorter but most v C \: C likely unstable due to frameshift and amino acid substitution at the carboxy terminal. The deletion of a single nucleotide (G) between nucleotides 1301 and 1305 (CGGGGGC + CGGGGC) in exon 10 of patient CR. which was also found in genomic DNA, resulted in frameshift, premature termination at codon 444, and either reduced transcription or unstable mRNA (Fig 2, lane 12) .
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DISCUSSION
To explore whether all WAS patients, irrespective of the clinical phenotype, have mutations of the WAS gene, we selected for mutation analysis 13 unrelated patients with clinical and laboratory findings that ranged from isolated platelet anomalies, characteristic for XLT, to the classic WAS phenotype.
Using the dideoxy fingerprinting method for rapid screening, followed by sequence analysis of both cDNA and genomic DNA, we were able to identify mutations of the WAS gene in 9 boys with classic WAS and in 4 with thrombocytopenia and small platelets. The most common mutations observed were point mutations of genomic DNA that resulted in either amino acid substitutions, the generation of termination codons, or the insertion or deletion of segments of cDNA. Only 3 of the 12 mutations identified were due to mutations other than single point mutations of genomic DNA. These mutations include insertions and deletions of single or multiple base pairs resulting in frameshift and amino acid substitutions followed by early termination. Of the 18 unique mutations of the WAS gene reported to dateI3.l9 (Fig l) , 3 affected arginine 86, suggesting that codon 86 may be a mutation hot spot. Substitution of arginine with cysteine (2 patients reported here) resulted in a mild phenotype; substitution with leucine or with histidine" resulted in a classic phenotype.
A simple scoring system to assess disease severity was designed to clearly identify patients with a mild phenotype resembling XLT. Three of the four unrelated XLT patients included in the analysis were found to have point mutations resulting in amino acid substitutions within exon 2 (Arg86-Cys in 2 patients and Ala47Asp in 1 patient). The fourth patient with XLT had a point mutation within exon 9, resulting in the creation of a new splice site. This new splice site caused the deletion of 13 nucleotides and resulted in frameshift and the formation of a truncated and most likely unstable protein. It is possible that the circulating lymphocytes of the affected members of this family express two populations of mRNA: one having the deletion and the other a less detritmental missense mutation, Met307Val. Villa et all9 recently reported three unique mutations of the WAS gene in 3 unrelated boys with thrombocytopenia and small size platelets. Two of their patients had missense mutations within exon 2 and exon 7, respectively. The third mutation reported was more complex, consisting of a single nucleotide insertion, which resulted in frameshift and termination in exon 5. At this time, without knowing the function of the WAS protein, it is difficult to understand why mutations Of the 9 patients with classic WAS phenotypes (score 3 to 5), only 1 had a simple missense mutation. Of the remaining 8 patients, 2 had nonsense mutations affecting exons 1 and 10, respectively, and 6 had complex mutations resulting in deletions or insertions, frameshift, and early termination. Sequence analysis of R " s genomic DNA showed a C + T transition at nucleotide 329, introducing a nonsense codon. However, the RT-PCR product consisted of two cDNA populations: one was of normal size and contained the termination codon and the other was shorter in size due to a deletion of 87 nucleotides. This deletion was found to represent the 5' section of the exon described as exon 3 in our original r e p~r t . '~ Reexamination of this region showed that this exon was divided by a 100-nucleotide-long intron into two exons: the 87-nucleotide-long exon 3 and the 102-nucleotide-long exon 4 (see erratum to Deny et al,13 and Ochs et all4). Sequence analysis of the exodintron junctions surrounding the deleted exon failed to identify alternative splice sites that could account for the skipping of exon 3. Thus, the nonsense mutation at position 329 must be responsible for the deletion of exon 3 in the majority of the gene transcripts. Skipping of exons containing nonsense mutations has been observed in the fibrillin gene FBNl, which is responsible for Marfan's syndrome"; in the cystic fibrosis gene"; and in the gene involved in the complementation group C of Fanconi anemia:* suggesting that nonsense mutations may alter the selection or the effectiveness of regional splice site^.'^,^^ The reduced amount of mRNA found in this patient's B-LCL, suggesting insufficient transcription or unstable mRNA, shows that the resulting protein is not only truncated but also diminished, which is compatible with a severe clinical phenotype.
Exodintron splice junction mutations were observed in two unrelated families. Although both of these mutations were t + c transitions at position+2 of the 5' splice site of intron 9 and 11, respectively, the consequences on transcription were different, depending which intron was affected. The t + c transition 5' of intron 9 resulted in the activation of an alternative splice site, the inframe addition of 114 nucleotides derived from intron 9, the generation of a termination codon within the inserted segment and a severely diminished transcript. The t + c transition 5' of intron 11 resulted in the skipping of exon 11, the loss of 1 15 nucleotides, an out of frame transcript, a truncated protein, and a normal amount of transcript. For 5' splice sites, the generation of an alternative splice site is dependent on the presence of such a site in the vicinity of the mutation site and on a certain degree of homology between the sequences of the old and the new splice sitesm In both patients, the consensus sequence at the exodintron junction, Ggtgag, was mutated to Ggcgag. In patient MB, a cryptic splice site, located 114 bp 3', with the sequence TGgtcag, was available, whereas in patient BM, no such cryptic splice site existed, and, as a consequence, exon 11 is skipped.
The tools are now available to identify mutations within the WAS gene, to confirm the diagnosis in patients with atypical phenotypes, to recognize carrier females, and to perform prenatal diagnosis. However, despite cloning the WAS gene and progress in identifying unique mutations, little is known about the function of the WAS protein and its role in the normal development of T and B lymphocytes and the production of platelets. Analysis of the effect of naturally occurring mutations of the WAS gene on cell function should provide new insights into the regulation of the immune response and platelet homeostasis.
